anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Venetoclax and AMG 176 will be administered in combination. Different combinations of dose levels for venetoclax and AMG 176 will be explored.
Antibiotic TF-500, an immune-stimulating tumor inhibitor, is obtained from Fusobacterium nucleatum ATCC 31647. Thus, bacteria that had been cultured on an undefined medium contg. peptone, brain-heart infusion, glucose, and lactose were removed from the broth by filtration. The cells were defatted, washed with EtOH and acetone, and dried. A 320-g portion of cells was suspended in 400 ml DMSO and extd. by stirring at 65≰C for 4 hrs. The ext. was filtered and 2.5 l acetone and 10 ml concd. HCl were added, resulting in a ppt. The ppt. was purified by ultrafiltration twice on a UK-50 membrane and filtration through a Millipore filter with 0.2-μm pores. TF-100 has a mol. wt. of 50,000 - 200,000 and contains 12-30% carbohydrate and ± 10% protein.
The invention discloses polygonum multiflorum health wine and a brewing process thereof, belonging to the technical field of liquor brewing processes. The polygonum multiflorum health wine is prepared from the following raw materials in parts by weight: 50-70 parts of polygonum multiflorum, 15-25 parts of sticky rice, 15-25 parts of corns, 0.5-1.5 parts of distiller yeast, 1-3 parts of radix codonopsis, 2-4 parts of eucommia ulmoides, 1-3 parts of radix rehmannia preparate, 1-3 parts of flos carthami and 2-4 parts of jujubes. The brewing process of the polygonum multiflorum health wine comprises the following steps: crushing, steaming, fermenting and distilling. The polygonum multiflorum health wine disclosed by the invention is golden yellow, has ginseng wood faint scent in smell, and sweet and smooth mouthfeel, has the effects of refreshing, leaving fragrance in mouth and nose, having no foreign flavor, not causing thirst, headaches as well as headaches after a sleep, quickly dispelling the effects of alcohol, and the like, and meets the needs of different crowds. Meanwhile, the polygonum multiflorum health wine is simple in brewing process and relatively low in cost. And the materials are easily available.
The increasing availability of small hand held medical devices is a novel opportunity to develop a tool that guides patients through the decision-taking processes of seeking medical attendance during symptoms suggestive of acute myocardial infarction. The cornerstone of early diagnosis, risk stratification and treatment is the presence of ST segment elevation during symptoms suggestive of STEMI. Therefore, a hand held medical device that can detect ST segment elevation with high sensitivity and specificity could be a breakthrough in the further reduction of fatality from acute myocardial infarction. A number of conditions of the tool must be fulfilled to allow save use with a low threshold in the general population. Most important is the accuracy to detect any new ST segment elevation related to an acute artery occlusion. For more than 30 years the 12-lead ECG is the gold standard for detection of ST elevation. However, acute coronary occlusions of a posterior or lateral segment are not always detected by the gold standard. Moreover, in the very early phase of acute coronary occlusion, the accuracy 12 lead ECG is inadequate.

In a previous study "Diagnostic accuracy of a novel method for detection of acute transmural myocardial ischemia based upon a self-applicable 3-lead configuration" the investigators developed and validated a sensitive and specific 3-lead ECG method (RELF method). The method includes a new lead configuration and a new algorithm to analyze the ECG recordings based on an intra-individual comparisons of ST levels. In summary, a 3-lead recording from a healthy subject or from a patient with an acute coronary occlusion is compared automatically to one or more previous reference recordings from the same individual. The individualized ST shift is used as a decision variable to detect or reject an acute coronary artery occlusion. The RELF method was more accurate then the simultaneously applied 12-lead ECG which had a lower sensitivity and specificity. In that study all recordings were performed by a sophisticated ECG recording system. The RELF method is designed to be applicable also by small hand held ECG devices such as the self-applicable Mini RELF device.

In the current study the investigators aim to evaluate the accuracy of Mini RELF device relative to the 12 lead ECG when the device is self-applied on a daily basis by patients with coronary artery disease. In a parallel study (RELF IIb) the investigators aim to evaluate the specificity of the RELF method when it is self-applied by healthy subjects who are representative for future users of the device.
This study intended to analyze the effects of body weight control by the diet, training adaptation, and gut microbiota metabolites of wrestlers in the week leading up to competition. According to the weight difference of wrestlers from the target weight 1 wk before the competition, those whose weight control effectiveness is less than 2 kg were classified as the CW group, whereas more than 2 kg were classified as the CnW group. The body weight, body composition, and diet of wrestlers were recorded; urine samples were taken for standard urine testing, and stool samples were collected for the analysis of gut microbiota and metabolites. The data showed that the relative values of carbohydrate and fat energy in the CnW group were significantly higher than those of the CW group, but the relative values of protein energy were significantly lower. The white blood cells, occult blood, and protein appeared in urine in the CnW group. The microbiota with higher abundance values in the CnW group were positively correlated with the relative value of carbohydrate energy, while the abundance value of Streptococcus was negatively correlated, and the functional prediction of differential bacteria was related to riboflavin and selencompound metabolism. The differential metabolites of CW/CnW group were functionally enriched in the processes of lipid and amino acid metabolism. Overall, the extent of weight control in wrestlers was correlated with sensible dietary patterns, adaptability to training load, and distinct gut microbiota and metabolites.NEW & NOTEWORTHY The purpose of this study is to observe the differences in precompetition diet structure, adaptability to training, gut microbiota, and metabolites of wrestlers with different weight control effects and analyze the correlation between them, aiming to provide scientific guidance and advice on weight control for wrestlers.
An experimental model using pazopanib-induced cardiotoxicity is provided. The experimental model using pazopanib-induced cardiotoxicity includes administering an effective dosing regimen of pazopanib to induce a cardiotoxicity in a subject. The induced cardiotoxicity may include hypertension, arrhythmia, or cardiac toxicity. The dosing regimen may include administering a single dose or administering one or more daily doses of pazopanib. The dosing regiment may continue for a period of time between at least 10 and at least 30 days. The dose of pazopanib may be between 25 and 350 mg/kg.
Effective treatment of myocardial ischemia-reperfusion (MIR) injury remains an unmet clinical need. Cardiomyocyte apoptosis is common at this stage and poses a significant risk. Corylin, a flavonoid compound extracted from Psoralea corylifolia L., has been shown to have anti-inflammatory, anticancer, and antiatherosclerotic properties. However, whether and how corylin affects MIR injury remain unclear. In this study, we explored the mechanism of corylin as a potent therapeutic agent for MI/R injury, using a left anterior descending (LAD) coronary artery ligation and oxygen-glucose deprivation and reperfusion (OGD/R) model in vivo and in vitro. TUNEL, Annexin-V/PI double staining,Ki67 immunohistochemistry, western blot analysis, and immunofluorescence were used to validate cell apoptosis level and Raf-1/ASK1 complex activity. The interaction between corylin and Raf-1/ASK1 complex was detected using molecular docking, corylin-Raf-1 binding assays, and coimmunoprecipitation (Co-IP). Moreover, TTC staining, echocardiography, HE staining, Masson trichrome staining and serological testing were performed to assess the cardioprotective effects of corylin in vivo. These findings showed that corylin reduces MIR injury-induced cardiomyocyte apoptosis and improves cardiac function. Mechanistically, corylin can interact with Raf-1 and promote the formation of the Raf-1/ASK1 complex, thus inhibiting cardiomyocyte apoptosis. In conclusion, our results demonstrate that corylin ameliorated cardiac dysfunction after MIR injury by reducing myocardial apoptosis.
FIELD: medicine, dermatology, oncology. SUBSTANCE: medicinal composition has nitric acid, copper nitrate, dimethylsulfoxide and water. Composition is prepared by usual mixing procedure and can be used for treatment of patients with benign tumors (adenomas, fibromas), among them, of viral etiology (all forms of warts, molluscum contagiosum) and precancer skin diseases (keratomas, keratoacanthomas, cylindromas and others). Invention provides the enhancement of keratoplastic and antiviral effect of composition on tissues of pathological neoplasm, its accelerated penetration into tissues, decrease of aggressive adverse response to normal skin that results to stable curative effect. Treatment effectiveness is increased from 60-70% to 96.7% as compared with prototype. EFFECT: enhanced effectiveness of composition and treatment. 1 tbl
Abstract The present invention is directed to diabody molecules and uses thereof in the treatment of a variety of diseases and disorders, including immunological disorders, infectious disease, intoxication and cancers. The diabody molecules of the invention comprise two polypeptide chains that associate to form at least two epitope binding sites, which may recognize the same or different epitopes on the same or differing antigens. Additionally, the antigens may be from the same or different molecules. The individual polypeptide chains of the diabody molecule may be covalently bound through non-peptide bond covalent bonds, such as, but not limited to, disulphide bonding of cysteine residues located within each polypeptide chain. In particular embodiments, the diabody molecules of the present invention further comprise an Fc region, which allows antibody-like functionality to engineered into the molecule. - 253 2119227vl
PURPOSE: A method for producing a large amount of S-dihydroxyfarnesic acid methyl ester is provided to obtain the compound with excellent melanogenesis prevention. CONSTITUTION: A method for producing a large amount melanogenesis inhibitors comprises: a step of culturing insect-derived fungi and preparing a spawn culture medium; a step of inoculating the spawn culture medium to a medium containing a carbon source of glucose, fructose, sucrose, or dextrin and a nitrogen source of tryptone or CSL(corn steep liquor); a step of culturing the mixture. The spawn culture medium is prepared by culturing an insect-derived fungi-inoculated medium at 25-27 Deg. C. for 5-7 days; and a step of inoculating the fungi culture at 160-180 rpm and 25-27 Deg. C. for 3-4 days. A melanogenesis inhibitor contains a melanogenesis inhibiting material, S-(-)-10,11-Dihydroxyfarnesic acid methyl ester.
Sickle cell disease (SCD) is the most common inherited blood disorder in the U.S. and disproportionately affects African Americans and Hispanics. Approximately, 1,000 U.S. children are born with SCD annually. SCD results from abnormal hemoglobin and causes red blood cells (RBCs) to become misshaped ("sickle-shaped"). Sickled cells can block the flow of blood in small arteries causing tissue and organ damage and other life-threatening comorbidities. SCD complications can be serious and have a significant impact upon well-being and quality of life. Pain is the hallmark symptom associated with SCD, and is the most common clinical problem seen in children and the number one cause of SCD-related hospital admissions. If left untreated, these painful episodes can result in morbidity and mortality. Accurate assessment of pain specifiers (type, frequency, and intensity of pain) can help with ameliorating pain quickly and effectively. Despite children being accurate self-reporters of their pain, strategies which are effective and engaging to assist with pain identification are lacking. Reducing barriers to collection and promoting the value of accurate SCD pain assessment is a need in pediatric medicine. Pinpoint will be an innovative interactive assessment tool that engages patients while allowing physicians to collect important health data. This project will test the feasibility of applying gamification principles to develop a tablet application ("app") for 13-17 year olds with SCD. Specifically, this Phase I SBIR project will (1) develop a Pain Assessment Tool (PAT) to describe and categorize specific types of pain experienced by adolescents with SCD; and (2) create an app ("Pinpoint"), that will translate the PAT into gamified technology. The goal of Pinpoint is to engage adolescent patients and improve pain specification by developing a game-based pain assessment tool delivered via a tablet app to engage adolescent SCD patients, improve their pain specification self-report, and improve pain management by clinicians. The PAT will be developed using expert guidance from preeminent SCD clinicians. User-centered Design theory will be applied in the development of the app and will be guided by iterative cognitive interviews and focus groups with members of the target population, SCD teens. The project specific aims are to (1) develop the PAT using guidance from an Expert Advisory Board (EAB) of SCD clinicians; (2) conduct a series of cognitive interviews with adolescent SCD patients to guide and refine PAT development; (3) conduct iterative focus groups with adolescent SCD patients to guide and refine user interface design of the Pinpoint app; (4) program a functional Pinpoint prototype; and (5) conduct usability testing of the prototype with 13-17 year old SCD patients to assess functionality, navigation, and satisfaction. This project is innovative and timely. Pinpoint will be the first tablet app to identify and translate specific pain types for SCD into a gamified app using applied gamification principles.
Long-term animal studies have not been performed to evaluate the carcinogenic potential of MultiHance.

The results for MultiHance were negative in the following genetic toxicity studies: 1) in vitro bacteria reverse mutation assays, 2) an in vitro gene mutation assay in mammalian cells, 3) an in vitro chromosomal aberration assay, 4) an in vitro unscheduled DNA synthesis assay, and 5) an in vivo micronucleus assay in rats.

MultiHance had no effect on fertility and reproductive performance at IV doses of up to 2 mmol/kg/day (3 times the human dose on body surface basis) for 13 weeks in male rats and for 32 days in female rats. However, vacuolation in testes and abnormal spermatogenic cells were observed when MultiHance was intravenously administered to male rats at 3 mmol/kg/day (5 times the human dose on body surface basis) for 28 days. The effects were not reversible following 28-day recovery period. The effects were not reported in dog and monkey studies (at doses up to about 11 and 10 times the human dose on body surface basis for dogs (28 days dosing) and monkeys (14 days dosing), respectively).
The effects of combinations of ethambutol hydrochloride with other antituberculous drugs on the fetus is not known. While administration of this drug to pregnant human patients has produced no detectable effect upon the fetus, the possible teratogenic potential in women capable of bearing children should be weighed carefully against the benefits of therapy. There are published reports of five women who received the drug during pregnancy without apparent adverse effect upon the fetus.

Ethambutol is not recommended for use in pediatric patients under thirteen years of age since safe conditions for use have not been established.

Patients with decreased renal function need the dosage reduced as determined by serum levels of ethambutol, since the main path of excretion of this drug is by the kidneys.

Because this drug may have adverse effects on vision, physical examination should include ophthalmoscopy, finger perimetry and testing of color discrimination. In patients with visual defects such as cataracts, recurrent inflammatory conditions of the eye, optic neuritis, and diabetic retinopathy, the evaluation of changes in visual acuity is more difficult, and care should be taken to be sure the variations in vision are not due to the underlying disease conditions. In such patients, consideration should be given to relationship between benefits expected and possible visual deterioration since evaluation of visual changes is difficult. (For recommended procedures, see next paragraphs under ADVERSE REACTIONS.)

As with any potent drug, periodic assessment of organ system functions, including renal, hepatic, and hematopoietic, should be made during long-term therapy.
Congenital central hypoventilation syndrome (CCHS) is a rare genetic disorder of the autonomic nervous system resulting in decreased brain sensitivity to hypercapnia and hypoxia characterized by a genetic abnormality in the pair-like homeobox 2B (PHOX2B) gene. Most patients have a heterozygous expansion of the polyalanine repeat in exon 3 (PARM), while 10 % of patients have non-PARM (NPARM) mutations that can span the entire gene. The majority of pathogenic variants are de novo, but variants with incomplete penetrance can be identified in the heterozygous state. In the present report, CCHS was diagnosed in a symptomatic 3-month-old infant with neonatal respiratory distress. Genetic analysis revealed a new mutation in exon 1 of the PHOX2B gene - p.Ser28* (c.83C>G) - which was further identified in two family members, one minimally symptomatic and one asymptomatic. The identification of this new mutation supports the importance of sequencing the entire gene even when the classic PARM mutation is not found and highlights the phenotypic variability of CCHS.
Artegraft® vs Gore® Propaten®. Approximately 50 eligible patients with End Stage Renal Disease (ESRD) requiring hemodialysis will be randomized to receive one of these two grafts as part of their standard care.
OBJECTIVES: Monocyte distribution width (MDW) is a quantitative measurement of monocyte anisocytosis and has been proposed as an efficient marker for early sepsis detection. This study aimed to assess the prognostic potential of MDW in septic patients.
METHODS: In this study, a total of 252 adult septic patients were enrolled. Demographic, clinical, and laboratory finding including MDW and traditional inflammatory biomarkers detected at three time points (day 1, day 3 and day 6) after admission were collected and compared between 28-day survivors and non-survivors. Receiver operating characteristic (ROC) curves, Kaplan-Meier survival curve and Cox regression analyses were performed to assess and compare their predictive values. Group-based trajectory modeling was applied to identify MDW trajectory endotypes. Basic characteristics and 28-day outcomes were compared between the trajectories.
RESULTS: ROC curve analysis showed that MDW levels measured on day 3 after admission (D3-MDW) had moderate prognostic value and was independently associated with 28-day mortality in patients with sepsis. A D3-MDW value of 26.20 allowed discrimination between survivors and non-survivors with a sensitivity of 77.8 % and a specificity of 67.6 %. However, the prognostic accuracy of D3-MDW was diminished in immune-compromised patients and patients who already received antibiotics before admission. Group-based trajectory modeling indicated that excessively elevated and delayed decreased MDW levels during the first week after admission inversely correlated with prognosis.
CONCLUSIONS: MDW values detected on day 3 after admission and its kinetic change might be potential markers for predicting short-term outcome in adult septic patients.
The invention discloses a traditional Chinese medicine preparation for treating pressure sores. The traditional Chinese medicine preparation comprises 10 to 20 parts of hydrargyrum oxydatum crudum, 10 to 20 parts of calomel, 25 to 35 parts of calcined dragon bone, 25 to 35 parts of dragon's blood, 15 to 25 parts of elephant hide stir-fried by sand, 2 to 8 parts of borneol, 15 to 25 parts of frankincense, 10 to 20 parts of blood amber and 25 to 35 parts of catechu. The traditional Chinese medicine preparation adopts traditional and authentic Chinese herbal medicines as raw materials, and is prepared through a traditional preparation method according to a traditional Chinese medical principle of decayed tissue removal and skin regeneration. The traditional Chinese medicine preparation can be uniformly scattered on the surface of a wound, and promote falling off of decayed and necrotic tissue, fast improvement of blood circulation of a wound, fast necrolysis, fast growth of regenerated granulation tissue, and fast healing of an ulcerated wound. Therefore, the traditional Chinese medicine preparation realizes the purpose of thorough and fast cure of pressure sores. The traditional Chinese medicine preparation has the advantages of no need of an operation, no pain, convenient operation, reliable curative effect, high cure rate, high economical efficiency and good cost performance.
The invention discloses a new application of indirubin. Indirubin is a main component contained in indigo naturalis, and has a chemical structure of a bi-indole compound. Indirubin has inhibition effect on various transplantable animal tumors, and can destroy leukemia cells; indirubin can also enhance the phagocytosis effect of mononuclear phagocyte systems of animals. According to the invention, indirubin can reduce the arsenic content in body blood. Arsenic is a toxic substance with severe harm to human body. Research shows that when compared with a blank control group, rats administrated with indirubin have obviously reduced arsenic concentration in blood.
The study has 4 Cohorts. Each Cohort has 4 Cycles. For Cohorts 1-3, the dosing regimen will be every 14 days for 3 doses, followed by administration once every 28 days for three doses. For Cohort 4, the dosing regimen will be modified. Participants will receive one dose of MT-302 every week for 3 doses, followed by administration once every 28 days for three additional doses.

A Safety Review Committee (SRC) will provide oversight for this study. The primary responsibility of the SRC is to safeguard study participants by reviewing and assessing the clinical safety data being collected during the conduct of the study.
Core Size Arm patients (n=213) are treated with small size stent (8, 12, 15, 18 and 23 mm length). There are no significant difference between both the groups with respect to patient background, ischemic status, risk factors and medical history, numbers of target lesions and the lesion types, target lesion treatment, number of stents implanted, and target lesion characteristics other than lesion lengths.